Clinical trial
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
NCT00053482 · Emergent BioSolutions, Industry · Completed
Key facts
| NCT number | NCT00053482 |
|---|---|
| Title | Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults |
| Official title | The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination |
| Lead sponsor | Emergent BioSolutions, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smallpox |
| Intervention type | Biological |
| Interventions | ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® |
| Enrollment | 357 |
| Start date | Jan 1, 2003 |
| Primary completion | Apr 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Jan 31, 2003 |
| Last update posted | Mar 18, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: